158461-53-1

Upstream product

• 53078-85-6 2-bromo-5-methylaniline 
• 1692-25-7 3-pyridylboronic acid 
• 89-62-3 4-methyl-2-nitroaniline 
• 110-86-1 pyridine 
• 4373-73-3 3-(4-methyl-2-nitro-phenyl)-pyridine 

Downstream Products

• 119289-86-0 [1-Methyl-2-(5-methyl-2-pyridin-3-yl-phenylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester 
• 1296770-68-7 C₁₂H₁₀N₄ 
• 1296770-91-6 CF₃O₃S^(1-)*C₁₃H₁₃N₄⁽¹⁺⁾ 
• 119289-99-5 3-<2-(N-Boc-3-aminobutyramido)-4-(methyl)phenyl>pyridine 

Relevant academic research and scientific papers

Ruthenium-catalyzed γ-carbolinium ion formation from aryl azides; Synthesis of dimebolin

A range of γ-carbolines were produced stereoselectively from ruthenium(III)-catalyzed reactions of 3-pyridyl substituted aryl azides. Other catalysts and conditions were neither as selective nor as high-yielding. This method was used to synthesize dimebolin in a concise and efficient manner.

COMPOUNDS USEFUL FOR INHIBITING CHK1

Substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as ther-apeutic agents, for example, in treating cancer and oth

QUINOLINE DERIVATIVES

The present invention relates to compounds of Formula I, wherein R1, R2, R3, R4, and n are as defined, and to pharmaceutically acceptable salts of said compounds. Compounds of Formula I have activity in agonizing 5HT7 receptors and are useful in treating, for example, disorders that can be treated by modulating circadian rhythms.

Synthesis and antiarrhythmic activity of disubstituted phenylpyridine derivative

A series of disubstituted phenylpyridine derivatives was synthesized and their antiarrhythmic effects against chloroform-induced ventricular arrhythmias in mice were examined. Among them, 2- and 3-[2-(3- aminobutyramido)-4-(2,2,2-trifluoroethoxy)phenyl]pyridines (23h, 24h) and 3- [2-(3-aminobutyramido)-4-ethoxyphenyl]pyridine (24i) showed potent antiarrhythmic activity. They had approximately twice the potency of mexiletine (III). Compound 24i was selected from this series as a candidate for further development; it was found to have a class I B electrophysiological character and to show a slow kinetic rate-dependent block (RDB) of the sodium channel in cardiac muscle.